Charles Schwab Investment Management Inc. Acquires 7,344 Shares of Krystal Biotech, Inc. $KRYS

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Krystal Biotech by 3.0%, acquiring an additional 7,344 shares to hold 250,514 shares valued at approximately $45.17 million.
• Krystal Biotech recently reported quarterly earnings of $1.29 per share, surpassing estimates, with revenue of $96.04 million, indicating strong financial performance.
• Analysts maintain a consensus rating of "Buy" for Krystal Biotech, with price targets ranging from $166.00 to $240.00, suggesting potential upside despite recent price adjustments.

Charles Schwab Investment Management Inc. increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 3.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 250,514 shares of the company's stock after acquiring an additional 7,344 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.87% of Krystal Biotech worth $45,168,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in KRYS. Fifth Third Bancorp lifted its stake in Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Krystal Biotech in the fourth quarter worth $95,000. GAMMA Investing LLC lifted its stake in Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after acquiring an additional 432 shares during the period. Elevation Point Wealth Partners LLC purchased a new position in Krystal Biotech during the first quarter valued at $223,000. Finally, Avanza Fonder AB lifted its position in Krystal Biotech by 66.0% during the first quarter. Avanza Fonder AB now owns 1,260 shares of the company's stock valued at $228,000 after buying an additional 501 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the sale, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 49,800 shares of company stock worth $7,487,943 in the last ninety days. 13.70% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have commented on KRYS. Guggenheim lowered their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Chardan Capital reissued a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research report on Tuesday, August 5th. Citigroup reissued a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Friday, July 25th. Finally, Bank of America lowered their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $210.75.

Krystal Biotech Stock Down 0.1%

Shares of NASDAQ:KRYS traded down $0.16 on Thursday, hitting $145.70. 202,687 shares of the company traded hands, compared to its average volume of 427,586. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $207.84. The stock has a 50 day simple moving average of $143.96 and a 200-day simple moving average of $154.67. The company has a market cap of $4.22 billion, a PE ratio of 29.61 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).